Human Genome Skids

John Hancock advances; Biosite falls; plus more of today's stocks in the news

Human Genome Science (HGSI ) says a Phase II clinical trial of topically administered repifermin in adults with chronic venous ulcers did not meet its targets. UBS Financial sees a buying opportunity. S&P maintains hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.